NKTR-262

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameNKTR-262
Drug Alias NameNKTR-262
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 8 agonistsToll like receptor 7 agonists
TargetsToll like receptor 8Toll like receptor 7
Therapy Area/IndicationsColorectal NeoplasmsTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNektar Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNektar Therapeutics
Active IndicationsN/A
Inactive IndicationsColorectal NeoplasmsTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[7] 

Other Information

ATC CodeN/A
Related LinksN/A